New research suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who stop traditional lifestyle regimens.
Published data in a prominent health publication points out that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People using these treatments need to be informed of the risk of quick weight regain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
That rate of recovery implies a return to original weight within about one and a half years.
Comparing Approaches
The research, which looked at 37 of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers emphasize that individuals who shed pounds through dieting generally experience a less rapid creep back—around 0.1 kg a month—post-intervention.
The Reason for the Quick Regain
Experts propose the mode of action of the jabs explains the amplified regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of the hormone concentrations far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Issue?
The NHS advise the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, given the significant potential of weight regain, the therapy is often ongoing.
This view is echoed by drug manufacturers, who state that the results "highlight the persistent character of obesity," similar to managing conditions like diabetes.
Patient Accounts
Users who have stopped the medication explain a powerful resurgence of cravings.
"It felt as if a switch flipping and I was suddenly starving," said one woman.
This difficulty is worsened if patients have not adopted permanent lifestyle or habit changes during treatment.
Widespread Use
Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while the jabs are effective tools for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on ongoing behavioural management.
